CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A zero-spend month concentrates spending to essentials, directing more money toward debt. Plan, track, and celebrate smaller, steady wins.
16,055 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
After a rough stretch for tech shares, Micron stock bounced back, signaling a renewed interest in memory makers. This...
Private homebuilders are increasingly confronting leadership transitions that could affect loan access and project fu...
A bipartisan letter delivered to President Trump on June 14, 2026, asks for a concrete plan to preserve Social Securi...
Two consumer-facing stocks sit at a crossroads: GameStop is tightening its turnaround with a leaner footprint, while ...
A Vesta director recently sold roughly $203,000 worth of stock while the company’s shares have risen about 25% over t...
Twilio stocks have seen a pullback after a strong run. This guide explains how to assess whether you should twilio di...
Micron Technology has stunned investors with a massive year-long rally. This article breaks down the drivers behind t...
Richtech Robotics stock fell sharply in June after the company disclosed restatements. This guide breaks down what ha...
As economists flag recession risk and AI reshapes jobs, a new wave of stress tests workplaces. brené brown warns amer...
As pepsico (pep) 2026 earnings shape the near-term outlook, investors want clarity on growth drivers, costs, and capi...
Investing in rare earths is a long game tied to U.S. policy, global demand, and the pace of production. This guide co...